NCI

Syndax Pharmaceuticals To Collaborate with NCI to Develop Entinostat and SNDX-6352 as Cancer Treatment

Syndax Pharmaceuticals ( SNDX ) said Wednesday that it has entered into a cooperative research and development agreement with the National Cancer Institute ( NCI ), part of the National Institutes of Health, for intramural preclinical and clinical research.

As part of the agreement, Syndax will collaborate with the Laboratory of Tumor Immunology and Biology at the NCI to evaluate the therapeutic benefit of entinostat, an oral, Class 1 selective small molecule histone deacetylase inhibitor in development for the treatment for multiple cancers, and SNDX-6352, a humanized IgG4 monoclonal antibody with high affinity against colony-stimulating factor 1 receptor in development as a treatment of neoplastic diseases.

This complements the existing agreement in place with the NCI's Cancer Therapy Evaluation Program to evaluate entinostat in clinical trials.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.